New York79°

New York79°

Denver83°
May 30, 2020 CONTACT

Zynerba Pops, While GW Pharmaceuticals Drops

Zynerba (ZYNE)  stock jumped 53% on news that its results from a Phase 2 clinical trial for lead candidate ZYN002 with Fragile-X patients had positive results. The 20-subject study showed a 46% improvement from the baseline and had meaningful improvements in key behavioral characteristics. However, Alfredo Fontanini pointed out on Twitter @AF_biotech that when you look at the chart of the results, the placebo actually performed better than the treatment.

Fontanini provided a chart that wasn’t available through Zynerba’s press release, but he also noted that the MOA or mechanism of action was a positive result and that the company hit a home run there. Still, Fontanini noted that the results were “absolutely, uninterpretable data, worthless for FDA.” The company said it plans to meet with the FDA in the first half of 2018 to discuss a Phase 2/3 study.

GW Pharmaceuticals (GWPH) is off by 11% in early trading after competitor Zogenix (ZGNX) reported positive results for its drug for Dravet syndrome. Zogenix shot up over 140% to lately trade at $31.55 on news that its drug ZX008 reduced seizures. The patient’s seizures dropped significantly more than the placebo and had the longest seizure-free interval. Of course, this has been the disease that GW Pharmaceuticals has been working towards fighting, with so far, no real competition from any other drug players.

GW Pharma’s drug uses cannabis as its base compound, while Zogenix’s ZX008 uses fenfluramine hydrochloride. This was better known as fen-phen and was used as a diet pill before it was taken off the market in the 90’s.

Joseph Sullivan M.D., director of the Pediatric Epilepsy Center in UCSF Benioff Children’s Hospital San Francisco, and Principal Investigator of Study 1 in the U.S. said, “These results are truly exciting and demonstrate, in a large multicenter controlled trial, the impressive efficacy of low-dose fenfluramine for patients with Dravet syndrome. If approved, ZX008 could play an important role in treating this devastating condition.”

GW Pharmaceuticals was lately trading at $99.25 and has fallen 23% over the past year after reaching its 52-week high of $137.

Debra Borchardt

Debra BorchardtDebra Borchardt

Debra Borchardt is the CEO, Co-Founder, and Editor-In-Chief of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Masters degree in Business Journalism from New York University.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like


About Us

The Hemp Market Report will target news from the fast growing worlds of cannabidiol (CBD) and hemp. As a sister site to the Green Market Report, HMR will cover financial stories, but also take a look at lifestyle news as well. The Hemp Market Report will also publish sponsored content as we seek to expand our content offerings.


READ MORE



Recent Tweets

@GreenMarketRpt – 1 day

RT : A big thank you to the participants and attendees of yesterdays Arcview Access Elite, Sponsored by ! #cannabis…

@GreenMarketRpt – 1 day

$CGC ⁦@CanopyGrowth⁩ Delivers Staggering Billion Dollar Net Loss In Fourth Quarter #potstocks…

Back to Top

You have Successfully Subscribed!